Journal article
Meaningful improvement in general health outcomes with Guselkumab treatment for psoriatic arthritis: Patient-Reported Outcomes Measurement Information System-29 results from a phase 3 study
- Abstract:
-
Objective The Phase 3 DISCOVER-1 study of guselkumab is the first randomized controlled trial to use Patient-Reported Outcomes Measurement Information System (PROMIS) measures to assess the effects of treatment on general health outcomes in patients with psoriatic arthritis (PsA).
Methods Patients (N = 381) with active PsA were randomized 1:1:1 to guselkumab 100 mg every 4 weeks (Q4W); guselkumab 100 mg at Week 0, Week 4, then every 8 weeks (Q8W); or pla... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.3MB, Terms of use)
-
- Publisher copy:
- 10.1007/s40271-022-00588-6
Authors
Bibliographic Details
- Publisher:
- Springer
- Journal:
- Patient -- Patient-Centered Outcomes Research More from this journal
- Volume:
- 15
- Issue:
- 6
- Pages:
- 657–668
- Publication date:
- 2022-06-30
- Acceptance date:
- 2022-05-19
- DOI:
- EISSN:
-
1178-1661
- ISSN:
-
1178-1653
- Pmid:
-
35768650
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
1266857
- Local pid:
-
pubs:1266857
- Deposit date:
-
2022-07-20
Terms of use
- Copyright holder:
- Orbai et al
- Copyright date:
- 2022
- Rights statement:
- © The Author(s) 2022. Open Access: This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record